Want to see FR:ALTHE full AI Analyst Report?
Theraclion SA (ALTHE) AI Stock Analysis
Theraclion SA
(Paris:ALTHE)
The score is primarily constrained by persistent unprofitability, negative equity, high leverage, and ongoing cash burn. Positive price positioning above all major moving averages provides meaningful support, but negative earnings and the absence of a dividend keep the overall profile weak.
Theraclion SA (ALTHE) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 39.25M
- Dividend Yield
- ―
- Average Volume (3M)
- 79.46K
- Price to Earnings (P/E)
- -6.8
- Beta (1Y)
- 1.31
- Revenue Growth
- -16.98%
- EPS Growth
- 20.31%
- Country
- France
- Employees
- 36
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Theraclion SA Business Overview & Revenue Model
Company Description
Theraclion SA, established in 2004 and based in Malakoff, France, specializes in developing innovative echotherapy medical solutions. These treatments harness high-intensity focused ultrasound (HIFU) technology. Their offerings include SONOVEIN, a ro...
How the Company Makes Money
Theraclion’s revenues are primarily generated from the sale and/or placement of its therapeutic ultrasound systems to healthcare providers (e.g., hospitals, clinics, and specialty practices), along with recurring revenue from related disposables/cons...
Theraclion SA Financial Statement Overview
Summary
Very weak financial performance: persistent heavy losses, negative equity, high leverage, and consistently negative operating and free cash flow outweigh modest and volatile revenue.
Income Statement
18Very NegativeBalance Sheet
12Very NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.01M | 1.19M | 830.00K | 1.82M | 1.24M | 1.48M |
| Gross Profit | -7.62M | -6.21M | -7.18M | -1.08M | -3.05M | -4.54M |
| EBITDA | -7.26M | -5.98M | -5.92M | -4.49M | -5.74M | -4.40M |
| Net Income | -6.76M | -5.69M | -5.76M | -3.68M | -4.96M | -3.76M |
Balance Sheet | ||||||
| Total Assets | 14.78M | 12.51M | 11.47M | 18.66M | 13.94M | 11.83M |
| Cash, Cash Equivalents and Short-Term Investments | 5.22M | 3.38M | 4.17M | 7.82M | 2.52M | 2.49M |
| Total Debt | 4.95M | 5.09M | 1.30M | 1.95M | 2.51M | 2.39M |
| Total Liabilities | 15.18M | 15.10M | 11.47M | 13.01M | 13.40M | 13.10M |
| Stockholders Equity | -395.00K | -2.59M | -114 | 5.65M | 544.87K | -1.27M |
Cash Flow | ||||||
| Free Cash Flow | 0 | -7.16M | -3.01M | -2.60M | -5.59M | -4.03M |
| Operating Cash Flow | 0 | -7.16M | -2.91M | -2.48M | -5.27M | -3.88M |
| Investing Cash Flow | 0 | -414.00K | -188.00K | -213.52K | -739.63K | -524.46K |
| Financing Cash Flow | 0 | 6.78M | -545.00K | 7.99M | 6.03M | 4.56M |
Theraclion SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTHE, the sentiment is Positive. The current price of 0.70 is above the 20-day moving average (MA) of 0.63, above the 50-day MA of 0.66, and above the 200-day MA of 0.62, indicating a bullish trend. The MACD of 0.00 indicates Negative momentum. The RSI at 57.63 is Neutral, neither overbought nor oversold. The STOCH value of 92.61 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALTHE.
Theraclion SA Peers Comparison
Overall Rating
- FR:ALTHE54Neutral
FR:ALIKO46Neutral
FR:ALMKT45Neutral
FR:ALNOV45Neutral
FR:ALMDT43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| FR:ALTHE | 54Neutral | EUR 51.65M | -6.76 | 453.10% | ― | -16.98% | 20.31% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FR:ALIKO | 46Neutral | EUR 22.42M | -5.20 | -22.03% | ― | 37.28% | 7.83% |
| FR:ALMKT | 45Neutral | EUR 18.94M | 1.53 | -157.72% | ― | 3.38% | ― |
| FR:ALNOV | 45Neutral | EUR 31.94M | -0.76 | -159.70% | ― | 10.36% | 29.41% |
| FR:ALMDT | 43Neutral | EUR 180.85M | -3.00 | 271.64% | ― | 2.16% | -5.26% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALTHE | Theraclion SA | 0.70 | 0.05 | 7.69% | |
| FR:ALMKT | MAUNA KEA TECHNOLOGIES | 0.10 | -0.00 | -1.02% | |
| FR:ALNOV | Novacyt S.A. | 0.44 | -0.02 | -4.35% | |
| FR:ALDMS | Diagnostic Medical Systems | 0.91 | -0.41 | -30.95% | |
| FR:ALIKO | Ikonisys SA | 1.42 | -0.04 | -2.74% | |
| FR:ALMDT | Median Technologies | 3.69 | 0.79 | 27.24% |
Theraclion SA Corporate Events
Theraclion gains bullish TP ICAP Midcap coverage on Sonovein’s growth potential
Theraclion has received initial equity research coverage from TP ICAP Midcap, which starts with a Buy recommendation and a target price of EUR 1.70, implying a potential upside of 189% versus the latest closing price. The brokerage underscores Sonove...
Theraclion deepens losses as it ramps up for Sonovein’s global push and awaits FDA ruling
Theraclion reported a first-half 2026 operating loss of €3.9 million on revenue of €663,000, as higher regulatory, commercial and industrial costs weighed on earnings while the company prepared for the possible U.S. launch of Sonovein. Ca...
Theraclion Updates Share Capital and Voting Rights Structure
Theraclion has disclosed its latest share capital and voting rights figures, reporting 73,543,457 shares outstanding as of July 31, 2026. The company lists a theoretical total of 88,767,504 voting rights and an actual total of 86,957,843 voting right...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026